

| | | | | | | | |
|--|---|---------------------------------|--|-----------------|----------|------|----------|
| 藤原慶一, 安部隆三, 織田成人, 横須賀收 | 急性肝不全に対する人工肝補助の現状と high flow-volume HDF の展望 | 持田智 | 第 39 回日本急性肝不全研究会藤原研司先生メモリアル追悼文集・記録集 | アークメディア | 東京 | 2013 | 135-140 |
| 柄沢智史, 渡邊栄三, 安部隆三, 中田孝明, 大島拓, 服部憲幸, 織田成人 | 劇症肝炎(FH)に対するオンライン血液濾過透析(on-line HDF)の施行経験-高流量持続血液濾過透析(HFCHDF)との臨床効果の比較- | 持田智 | 第 39 回日本急性肝不全研究会藤原研司先生メモリアル追悼文集・記録集 | アークメディア | 東京 | 2013 | 153-156 |
| 鈴木一幸, 滝川康裕, 遠藤龍人, 宮坂昭生, 宮本康弘, 小野寺美緒, 小山富子, 岡本宏明, 伊藤清顕, 溝上雅史 | B 型急性肝炎および慢性肝疾患における HBV ゲノタイプ A の頻度と感染経路の検討 | 犬山シンポジウム記録刊行会 | ウイルス肝炎・肝癌の病態と治療 | メディカルトリビューン社 | 東京 | 2013 | 23 - 28 |
| 安井伸, 藤原慶一, 横須賀收 | HBV キャリア重症化の定義と核酸アナログ＋ステロイド併用療法 | 持田智 | 第 39 回日本急性肝不全研究会藤原研司先生メモリアル追悼文集・記録集 | アークメディア | 東京 | 2013 | 123-126 |
| 疋田隼人, 竹原徹郎 | 劇症肝炎の発症機序 ①アポトーシス・細胞死 | 竹原徹郎, 持田智, 大平 弘正, 坂井田功 | 難治性肝疾患の診療を極める (Hepatology Practice) | 文光堂 | 東京 | 2013 | In press |
| Inoue K, Yoshihara M. | Overview of Artificial Liver Support Systems in the World and New Promising Methods | Carmen Peralta, Luis Fontana | Liver Failure: Etiologies, Neurological Complications and Emerging Therapies | Nova Publishers | New York | 2013 | 159-176 |
| 荒田慎寿, 滝澤憲一, 野崎昭人, 近藤正晃, 森本 学, 沼田和司, 今成秀則, 田中克明 | 急性肝不全に対する on-line HDF の課題と展望 | 持田 智 | 第 39 回日本急性肝不全研究会藤原研司先生メモリアル追悼文集・記録集 | アークメディア | 東京 | 2013 | 146-149 |
| 高谷広章, 植村正人, 藤本正男, 松山友美, 森岡千恵, 石川昌利, 辻本達寛, 瓦谷英人, 北澤利幸, | 急性肝不全における血漿エンドシン濃度と ADAMTS13 活性の動態:新規治療法の可能性を含めて | 日本エンドトキシン・自然免疫研究会 (編) | エンドトキシン・自然免疫研究 16 自然免疫から自然炎症へ | 医学図書出版株式会社 | 東京 | 2013 | 16-19 |

| | | | | | | | |
|--|---|--------------------------------|---|-------------------------------|-------------|------|----------|
| 早川正樹, 松本雅則, 藤村吉博, 福井 博 | | | | | | | |
| 福井 博 | 劇症肝炎の発症機序 (微小循環障害) | 坂井田功, 大平弘正, 竹原徹郎, 持田智 | 難治性肝疾患の診 療を極める (Hepatology Practice) | 文光堂 | 東京 | 2013 | In press |
| 佐藤保則, 中沼安二 | 腫瘍性胆管・胆嚢疾患 | 中沼安二, 坂元亨宇, 福島敬宜 | 肝胆膵の実践病理 診断 | 文光堂 | 東京 | 2013 | 185-208 |
| 佐藤保則, 中沼安二 | 胆管系悪性腫瘍 | 中沼安二 | 肝臓病理テキスト | 南江堂 | 東京 | 2013 | 232-246 |
| 佐々木素子, 中沼安二 | 胆道粘液産生性腫瘍の 分子病理 | 小俣政男, 千葉勉 | 専門医のための消 化器病学 | 医学書院 | 東京 | 2013 | 547-548 |
| 鬼島宏, 中沼安二, 柳澤昭夫, 佐々木素子 | 胆道癌取扱い規約 [病 理] | 日本肝胆膵外 科学会編 | 胆道癌取扱い規約 (第6版) | 金原出版 | 東京 | 2013 | 1-93 |
| 正田純一 | トピックス：胆石形 成の分子機序 | 小俣政男, 千葉 勉 | 専門医のための消 化器病学 | 医学書院 | 東京 | 2013 | 494-496 |
| 正田純一, 松田厚志, 久野 敦, 池原 譲, 成松 久, 大河内信弘, 山本雅一, 中沼安二 | 肝内胆管癌の新規バイ オマーカー | 坂井田功, 大平弘正, 竹原徹郎, 持田智 | 難治性肝疾患の診 療を極める (Hepatology Practice) | 文光堂 | 東京 | 2013 | In press |
| 正田純一 | 胆道の炎症 | | 内科学書第 8 版 Vol.4 肝・胆道・膵 疾患 | 中山書店 | 東京 | 2013 | 349-351 |
| 正田純一 | 原発性硬化性胆管炎 | | 内科学書第 8 版 Vol.4 肝・胆道・膵 疾患 | 中山書店 | 東京 | 2013 | 352-353 |
| Shoda J, Kawamoto T, Yamamoto M. | Gallbladder Cancer - Pathogenesis and Molecular Targeting Strategies for Therapeutic Options. | Hiroto S.Watanabe | Horizons in Cancer Research | NOVA Science Publishers | New York | 2013 | 1-24 |

研究成果の刊行に関する一覧表（平成25年度）

雑 誌

| 発表者氏名 | 論文タイトル名 | 発表誌名 | 巻号 | ページ | 出版年 |
|---|--|------------------|-----|-------------|------|
| 恩地森一, 銭谷幹男, 山本和秀, 坪内博仁 | 自己免疫性肝炎の診断指針・治療指針 (2013年) | 肝臓 | 54 | 723-725 | 2013 |
| Yamamoto K, Miyake Y, Ohira H, Suzuki Y, Zeniya M, Onji M, Tsubouchi H; Intractable Liver and Biliary Diseases Study Group of Japan. | Prognosis of autoimmune hepatitis showing acute presentation. | Hepato Res | 42 | 630-638 | 2012 |
| Ohira H, Abe K, Takahashi A, Zeniya M, Ichida T. | Clinical features of hepatocellular carcinoma in patients with autoimmune hepatitis in Japan. | J Gastroenterol | 48 | 109-114 | 2012 |
| Nakano M, Saeki C, Takahashi H, Homma S, Tajiri H, Zeniya M. | Activated natural killer T cells producing interferon-gamma elicit promoting activity to murine dendritic cell-based autoimmune hepatic inflammation. | Clin Exp Immunol | 170 | 274-282 | 2012 |
| Zeniya M, Takahashi H. | Diagnostic criteria of autoimmune hepatitis—Historical review and present problem. | Jikeikai Med J | 58 | 89-93 | 2011 |
| 銭谷幹男 | 自己免疫性肝炎の診断・治療における最 近の知見 | 最新医学 | 67 | 1811-1816 | 2012 |
| Matsumoto K, Miyake Y, Umeda Y, Matsushita H, Matsuda H, Takaki A, Sadamori H, Nouse K, Yagi T, Fujiwara T, Yamamoto K. | Serial changes of serum growth factor levels and liver regeneration after partial hepatectomy in healthy humans. | Int J Mol Sci | 14 | 20704-20728 | 2013 |
| 三宅康広, 松本和幸, 大西敦之, 松下浩志, 高木章乃夫, 山本和秀 | 自己免疫性肝胆膵疾患の病態解明の進歩 自己免疫性肝炎における新規自己抗体 | 消化器と免疫 | 49 | 3-6 | 2013 |
| 阿部雅則, 恩地森一 | 肝胆膵疾患；予後の変遷 自己免疫性肝 炎の予後 | 肝胆膵 | 66 | 447-453 | 2013 |
| 阿部雅則, 恩地森一 | 肝臓治療学 自己免疫性肝疾患の治療 学 | 細胞 | 45 | 223-231 | 2013 |
| 阿部雅則, 恩地森一 | 自己免疫性疾患・アレルギー疾患（後編） それぞれの疾患の理解 自己免疫性肝炎 | 最新医学 | 68 | 1335-1343 | 2013 |

| | | | | | |
|---|---|------------------------|--------|-----------|------|
| Abe M, Hiasa Y, <u>Onji M.</u> | T helper 17 cells in autoimmune liver diseases. | Clin Dev Immunol | 2013 | 607073 | 2013 |
| Migita K, <u>Nakamura M</u> , Abiru S, Jiuchi Y, Nagaoka S, Komori A, Hashimoto S, Bekki S, Yamasaki K, Komatsu T, Shimada M, Kouno H, Hijioka T, Kohjima M, <u>Nakamuta M</u> , Kato M, <u>Yoshizawa K</u> , Ohta H, Nakamura Y, Takezaki E, Nishimura H, Sato T, Ario K, Hirashima N, Oohara Y, Naganuma A, Muro T, Sakai H, Mita E, Sugi K, Yamashita H, Makita F, Yatsuhashi H, <u>Ishibashi H</u> , Yasunami M. | Association of STAT4 polymorphisms with susceptibility to type-1 autoimmune hepatitis in the Japanese population. | PLoS One | 8 (8) | e71382 | 2013 |
| Kanno Y, Watanabe H, Takahashi A, Abe K, <u>Ohira H</u> | Anti-phosphoenolpyruvate carboxykinase 2 antibody in patients with autoimmune hepatitis. | Hepatol Res | | In press | |
| Kamimura K, Imai M, Sakamaki A, Mori S, Kobayashi M, Mizuno KI, Takeuchi M, Suda T, Nomoto M, <u>Aoyagi Y.</u> | Granulocytapheresis for the treatment of severe alcoholic hepatitis: a case series and literature review. | Dig Dis Sci | 59 (2) | 482-488 | 2014 |
| Osaki A, Suda T, Kamimura K, Tsuchiya A, Tamura Y, Takamura M, Igarashi M, Kawai H, Yamagiwa S, <u>Aoyagi Y.</u> | A safe and effective dose of cisplatin in hepatic arterial infusion chemotherapy for hepatocellular carcinoma. | Cancer Med | 2 | 86-98 | 2013 |
| Kamimura K, Suda T, Zhang G, <u>Aoyagi Y</u> , Liu D. | Parameters affecting image-guided, hydrodynamic gene delivery to swine liver. | Mol Ther Nucleic Acids | 2 | e128 | 2013 |
| Takeuchi M, Kobayashi M, Hashimoto S, Mizuno K, Kawaguchi G, Sasamoto R, Aoyama H, <u>Aoyagi Y.</u> | Salvage endoscopic submucosal dissection in patients with local failure after chemoradiotherapy for esophageal squamous cell carcinoma. | Scand J Gastroenterol | 48 | 1095-1101 | 2013 |
| Kobayashi Y, Kamimura K, Nomoto M, Sugitani S, <u>Aoyagi Y.</u> | Immunohistochemical character of hepatic angiomyolipoma: for its management. | Case Rep Med | 2013 | 298143 | 2013 |
| Suda T, Nagashima A, Takahashi S, Kanefuji T, Kamimura K, Tamura Y, Takamura M, Igarashi M, Kawai H, Yamagiwa S, Nomoto M, <u>Aoyagi Y.</u> | Active treatments are a rational approach for hepatocellular carcinoma in elderly patients. | World J Gastroenterol | 19 | 3831-3840 | 2013 |

| | | | | | |
|--|---|--------------------------|--------|-----------|------|
| Yamada K, Suda T, Komoro YS, Kanefuji T, Kubota T, Murayama T, Nakayama H, <u>Aoyagi Y.</u> | Low fat intake is associated with pathological manifestations and poor recovery in patients with hepatocellular carcinoma. | Nutr J | 12 | 79 | 2013 |
| Matsuda Y, Wakai T, Kubota M, Takamura M, Yamagiwa S, <u>Aoyagi Y.</u> , Osawa M, Fujimaki S, Sanpei A, Genda T, <u>Ichida T.</u> | Clinical significance of cell cycle inhibitors in hepatocellular carcinoma. | Med Mol Morphol | 46 | 185-192 | 2013 |
| Tamura Y, Suda T, Arii S, Sata M, Moriyasu F, Imamura H, Kawasaki S, Izumi N, Takayama T, Kokudo N, Yamamoto M, Iijima H, <u>Aoyagi Y.</u> | Value of highly sensitive fucosylated fraction of alpha-fetoprotein for prediction of hepatocellular carcinoma recurrence after curative treatment. | Dig Dis Sci | 58 | 2406-2412 | 2013 |
| Yano M, Ohkoshi S, Aoki YH, Takahashi H, Kurita S, Yamazaki K, Suzuki K, Yamagiwa S, Sanpei A, Fujimaki S, Wakai T, Kudo SE, Matsuda Y, <u>Aoyagi Y.</u> | Hepatitis B virus X induces cell proliferation in the hepatocarcinogenesis via up-regulation of cytoplasmic p21 expression. | Liver Int | 33 | 1218-1229 | 2013 |
| Matsuda Y, Wakai T, Kubota M, Osawa M, Takamura M, Yamagiwa S, <u>Aoyagi Y.</u> , Sanpei A, Fujimaki S. | DNA damage sensor γ -H2AX is increased in preneoplastic lesions of hepatocellular carcinoma. | Scientific World Journal | 2013 | 597095 | 2013 |
| Sato M, Matsuda Y, Wakai T, Kubota M, Osawa M, Fujimaki S, Sanpei A, Takamura M, Yamagiwa S, <u>Aoyagi Y.</u> | P21-activated kinase-2 is a critical mediator of transforming growth factor- β -induced hepatoma cell migration. | J Gastroenterol Hepatol | 28 | 1047-55 | 2013 |
| Yokoo T, Kamimura K, Suda T, Kanefuji T, Oda M, Zhang G, Liu D, <u>Aoyagi Y.</u> | Novel electric power-driven hydrodynamic injection system for gene delivery: safety and efficacy of human factor IX delivery in rats. | Gene Ther | 20 | 816-823 | 2013 |
| Ikarashi S, Nishikura K, Ajioka Y, <u>Aoyagi Y.</u> | Re-evaluation of phenotypic expression in undifferentiated-type early gastric adenocarcinomas using mucin core protein and CDX2. | Gastric Cancer | 16 | 208-219 | 2013 |
| Yamashita T, <u>Honda M.</u> , <u>Nakamoto Y.</u> , Baba M, Nio K, Hara Y, Zeng SS, Hayashi T, Kondo M, Takatori H, Yamashita T, Mizukoshi E, Ikeda H, Zen Y, Takamura H, Wang XW, Kaneko S. | Discrete nature of EpCAM+ and CD90+ cancer stem cells in human hepatocellular carcinoma. | Hepatology | 57 (4) | 1484-1497 | 2013 |

| | | | | | |
|---|--|--------------------------------|----------|-----------|------|
| Arihara F, Mizukoshi E, Kitahara M, Takata Y, Arai K, Yamashita T, Nakamoto Y, Kaneko S. | Increase in CD14+HLA-DR ⁻ /low myeloid-derived suppressor cells in hepatocellular carcinoma patients and its impact on prognosis. | Cancer Immunol Immunother | 62 (8) | 1421-1430 | 2013 |
| Maruoka R, Aoki N, Kido M, Iwamoto S, Nishiura H, Ikeda A, Chiba T, Watanabe N. | Splenectomy prolongs the effects of corticosteroids in mouse models of autoimmune hepatitis. | Gastroenterology | 145 | 209-220 | 2013 |
| Imai N, Ikeda K, Seko Y, Matsumoto N, Kawamura Y, Hosaka T, Kobayashi M, Saitoh S, Sezaki H, Akuta N, Suzuki F, Suzuki Y, Arase Y, Kumada H. | Transcatheter arterial chemotherapy with miriplatin for patients with hepatocellular carcinoma and chronic renal failure. | Nihon Shokakibyō Gakkai Zasshi | 108 (11) | 1872-1878 | 2011 |
| Hiramatsu N, Kurosaki M, Sakamoto N, Iwasaki M, Sakamoto M, Suzuki Y, Sugauchi F, Tamori A, Kakinnuma S, Matsuura K, Izumi N. | Pretreatment prediction of anemia progression by pegylated interferon alpha-2b plus ribavirin combination therapy in chronic hepatitis C infection: decision-tree analysis. | J Gastroenterol | 46 (9) | 1111-1119 | 2011 |
| Kurosaki M, Sakamoto N, Iwasaki M, Sakamoto M, Suzuki Y, Hiramatsu N, Sugauchi F, Tamori A, Nakagawa M, Izumi N. | Sequences in the interferon sensitivity-determining region and core region of hepatitis C virus impact pretreatment prediction of response to PEG-interferon plus ribavirin: data mining analysis. | J Med Virol | 83 (3) | 445-452 | 2011 |
| 保坂哲也, 鈴木文孝, 小林正宏, 瀬古裕也, 今井則博, 平川美晴, 川村祐介, 瀬崎ひとみ, 芥田憲夫, 鈴木義之, 斎藤聡, 荒瀬康司, 池田健次, 小林万利子, 熊田博光 | B型慢性肝疾患に対する核酸アナログ療法によるHBs抗原消失とその関連因子の検討 | 肝臓 | 52 (4) | 255-257 | 2011 |
| Suzuki F, Arase Y, Suzuki Y, Akuta N, Sezaki H, Seko Y, Kawamura Y, Hosaka T, Kobayabashi M, Saitoh S, Ikeda K, Kobayashi M, Kumada H. | Long-term efficacy of interferon therapy in patients with chronic hepatitis B virus infection in Japan. | J Gastroenterol | 47 | 814-822 | 2012 |
| Suzuki Y, Ikeda K, Suzuki F, Toyota J, Karino Y, Chayama K, Kawakami Y, Ishikawa H, Watanabe H, Wenhua Hu, Timothy Eley, McPhee F, Eric Hughes, Kumada H. | Dual oral therapy with daclatasvir and asunaprevir for patients with HCV genotype 1b infection and limited treatment options. | J Hepatol | 58 | 655-662 | 2013 |

| | | | | | |
|--|---|---------------|----|-----------|------|
| Toyota J, Ozeki I, Karino Y, Asahina Y, Izumi N, Takahashi S, Kawakami Y, Chayama K, Kamiya N, Aoki K, Yamada I, <u>Suzuki Y</u> , Suzuki F, Kumada H. | Virological response and safety of 24-week telaprevir alone in Japanese patients infected with hepatitis C virus subtype 1b. | J Viral Hepat | 20 | 167-173 | 2013 |
| Hirakawa M, Ikeda K, Kobayashi M, Kawamura Y, Hosaka T, Sezaki H, Akuta N, Suzuki F, <u>Suzuki Y</u> , Saitoh S, Arase Y, Kumada H. | Randomized controlled trial of a new procedure of radiofrequency ablation using an expandable needle hepatocellular carcinoma. | Hepatol Res | 43 | 846-852 | 2013 |
| Suzuki F, <u>Suzuki Y</u> , Sezaki H, Akuta N, Seko Y, Kawamura Y, Hosaka T, Kobayashi M, Saito S, Arase Y, Ikeda K, Mineta R, Watahiki S, Kobayashi M, Nakayasu Y, Tsuda H, Aoki K, Yamada I, Kumada H. | Exploratory Study on telaprevir given every 8h at 500mg or 750mg with peginterferon-alpha-2b and rivavirin in hepatitis C patients. | Hepatol Res | 43 | 691-701 | 2013 |
| Hosaka T, Suzuki F, Kobayashi M, Seko Y, Kawamura Y, Sezaki H, Akuta N, <u>Suzuki Y</u> , Saitoh S, Arase Y, Ikeda K, Kobayashi M, Kumada H. | Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection. | Hepatology | 58 | 98-107 | 2013 |
| Akuta N, Suzuki F, Seko Y, Kawamura Y, Sezaki H, <u>Suzuki Y</u> , Hosaka T, Kobayashi M, Hara T, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Kumada H. | Emergence of Telaprevir-Resistant Variants Detected by Ultra-Deep Sequencing After Triple Therapy in Patients Infected With HCV Genotype 1. | J Med Virol | 85 | 1028-1036 | 2013 |
| Kawamura Y, Saitoh S, Arase Y, Ikeda K, Fukushima T, Hara T, Seko Y, Hosaka T, Kobayashi M, Sezaki H, Akuta N, Suzuki F, <u>Suzuki Y</u> , Fukuzawa K, Hamada Y, Takahashi J, Kobayashi M, Kumada H. | Three-dimensional magnetic resonance imaging for stringent diagnosis of advanced fibrosis associated with nonalcoholic steatohepatitis. | Hepatol Int | 7 | 850-858 | 2013 |
| Seko Y, Ikeda K, Kawamura Y, Fukushima T, Hara T, Sezaki H, Hosaka T, Akuta N, Suzuki F, Kobayashi M, | Antitumor efficacy of transcatheter arterial chemoembolization with warmed miriplatin in hepatocellular carcinoma. | Hepatol Res | 43 | 942-949 | 2013 |

| | | | | | |
|--|---|------------------|----|-----------|------|
| <u>Suzuki Y</u> , Saitoh S, Arase Y, Kumada H. | | | | | |
| Hosaka T, Suzuki F, Kobayashi M, Seko Y, Kawamura Y, Sezaki H, Akuta N, <u>Suzuki Y</u> , Saitoh S, Arase Y, Ikeda K, Kobayashi M, Kumada H | Clearance of hepatitis B surface antigen during long-term nucleot(s)ide analog treatment in chronic hepatitis B: results from a nine-year longitudinal study. | J Gastroenterol | 48 | 930-941 | 2013 |
| Akuta N, Suzuki F, Fukushima T, Kawamura Y, Sezaki H, <u>Suzuki Y</u> , Hosaka T, Kobayashi M, Hara T, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Kumada H. | Prediction of Treatment Efficacy and Telaprevir-Resistant Variants after Triple Therapy in Patients Infected with HCV Genotype 1. | J Clin Microbiol | 51 | 2862-2868 | 2013 |
| Suzuki F, Hosaka T, <u>Suzuki Y</u> , Akuta N, Sezaki H, Hara T, Kawamura Y, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Kobayashi M, Watahiki S, Mineta R, Kumada H. | Long-term efficacy and emergence of multidrug resistance in patients with lamivudine-refractory chronic hepatitis B treated by combination therapy with adefovir plus lamivudine. | J Gastroenterol | | In press | 2013 |
| Akuta N, Suzuki F, Fukushima T, Kawamura Y, Sezaki H, <u>Suzuki Y</u> , Hosaka T, Kobayashi M, Hara T, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Kumada H. | Utility of detection of telaprevir-resistant variant for prediction of efficacy of treatment of hepatitis C virus genotype 1 infection. | J Clin Microbiol | 52 | 193-200 | 2014 |
| Arase Y, Kobayashi M, Kawamura Y, Suzuki F, <u>Suzuki Y</u> , Akuta N, Kobayashi M, Sezaki H, Saito S, Hosaka T, Ikeda K, Kumada H, Kobayashi T. | Impact of virus clearance for the development of hemorrhagic stroke in chronic hepatitis C. | J Med Virol | 86 | 169-175 | 2014 |
| Akuta N, Suzuki F, Kobayashi M, Hara T, Sezaki H, <u>Suzuki Y</u> , Hosaka T, Kobayashi M, Saitoh S, Ikeda K, Kumada H. | Correlation between hepatitis B virus surface antigen level and alpha-fetoprotein in patients free of hepatocellular carcinoma or severe hepatitis. | J Med Virol | 86 | 131-138 | 2014 |
| Kawakami Y, Ikeda K, Fukushima T, Hara T, Kobayashi M, Saitoh S, Sezaki H, Akuta N, | Potential of no-touch pincer ablation procedure for small hepatocellular carcinoma that uses a multipolar radiofrequency ablation system: an experimental animal study. | Hepatol Res | | In press | |

| | | | | | |
|--|--|-----------------|----|-----------|------|
| Suzuki F, Suzuki Y, Arase Y, Kumada H. | | | | | |
| Kawamura Y, Ikeda K, Fukushima T, Seko Y, Hara T, Sezaki H, Hosaka T, Akuta N, Kobayashi M, Saitoh S, Suzuki F, Suzuki Y, Arase Y, Kumada H | What Is the Most Effective Drug Delivery System for Cisplatin during the Treatment of Hepatic Tumors with Single-Session Transcatheter Chemotherapy? A Pilot Study. | Gut Liver | 5 | 576-584 | 2013 |
| Hara T, Akuta N, Suzuki F, Sezaki H, Suzuki Y, Hosaka, Kobayashi M, Saitoh, Kumada H. | A pilot study of triple therapy with telaprevir, peginterferon and ribavirin for elderly patients with genotype 1 chronic Hepatitis C. | J Med Virol | 85 | 1746-1753 | 2013 |
| Kobayashi M, Hosaka T, Suzuki F, Akuta N, Sezaki H, Suzuki Y, Kawamura Y, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Miyakawa Y, Kumada H. | Seroclearance rate of hepatitis B surface antigen in 2,112 patients with chronic hepatitis in Japan during long-term follow-up. | J Gastroenterol | | In press | 2013 |
| Imai N, Ikeda K, Seko Y, Kawamura Y, Sezaki H, Hosaka T, Akuta N, Kobayashi M, Saitoh S, Suzuki F, Suzuki Y, Arase Y, Kumada H. | Transcatheter arterial chemotherapy with miriplatin for hepatocellular carcinoma patients with chronic renal failure: report of three cases. | Gut Liver | 7 | 246-251 | 2013 |
| Ogura S, Saitoh S, Kawamura Y, Sezaki H, Hosaka T, Akuta N, Kobayashi M, Suzuki F, Suzuki Y, Arase Y, Ikeda K, Kumada H. | Magnetic resonance laparoscopy: A new non-invasive technique for the assessment of chronic viral disease. | Hepatol Res | 43 | 836-845 | 2013 |
| Akuta N, Suzuki F, Seko Y, Kawamura Y, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Kumada H. | Efficacy and anticarcinogenic activity of ribavirin combination therapy for hepatitis C virus-related compensated cirrhosis. | Intervirolgy | 56 | 37-45 | 2013 |
| Seko Y, Akuta N, Suzuki F, Kawamura Y, Sezaki H, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Kumada H. | Amino acid substitutions in the hepatitis C Virus core region and lipid metabolism are associated with hepatocarcinogenesis in nonresponders to interferon plus ribavirin combination therapy. | Intervirolgy | 56 | 13-21 | 2013 |

| | | | | | |
|--|---|-----------------|------------------|-----------|------|
| Harada K, Kakuda Y, Nakamura M, Shimoda S, Nakanuma Y. | Clinicopathological significance of serum fractalkine in primary biliary cirrhosis. | Dig Dis Sci | 58 | 3037-43 | 2013 |
| Inamine T, Higa S, Noguchi F, Kondo S, Omagari K, Yatsunami Y, Tsukamoto K, Nakamura M. | Association of genes involved in bile acid synthesis with the progression of primary biliary cirrhosis. | J Gastroenterol | 48 | 1160-1170 | 2013 |
| The Intractable Hepatobiliary Disease Study Group supported by the Ministry of Health, Labour and Welfare of Japan, Working Subgroup (English version) for Clinical Practice Guidelines for Primary Biliary Cirrhosis. | Guidelines for the management of primary biliary cirrhosis. | Hepatol Res | 44 (Suppl. 1) | 71-90 | 2014 |
| 廣原淳子, 仲野俊成, 關 壽人, 岡崎和一, 中沼安二, 坪内博仁 | 原発性胆汁性肝硬変 (PBC) 全国調査にみる本邦 PBC の病態と予後の変遷 | 日本消化器病学会雑誌 | 110 (1) | 8-15 | 2013 |
| 小森敦正, 石橋大海, 中村稔, 八橋弘 | 原発性胆汁性肝硬変の予後 | 肝胆臓 | 66 | 455-461 | 2013 |
| 相葉佳洋, 小森敦正, 長岡進矢, 阿比留正剛, 右田清志, 伊東正博, 石橋大海, 八橋 弘, 中村 稔 | 自己免疫性肝胆臓疾患の病態解明の進歩. 原発性胆汁性肝硬変患者における TL1A と DcR3 の臨床学的意義 | 消化器と免疫 | 49 | 15-17 | 2013 |
| 石橋大海, 小森敦正 | 原発性胆汁性肝硬変 (PBC) の診療ガイドライン | 消化器の臨床 | 16 (2) | 117-122 | 2013 |
| 石橋大海, 下田慎治, 中村 稔 | 原発性胆汁性肝硬変の自己抗原は何か | 分子消化器病 | 10 | 131-137 | 2013 |
| 石橋大海, 下田慎治, 中村 稔 | 【自己免疫疾患・アレルギー疾患(後篇)それぞれの疾患の理解】臓器特異的自己免疫疾患 原発性胆汁性肝硬変 | 最新医学 | 68 (6) 増刊号 | 1326-1334 | 2013 |
| 中村 稔 | PBC の疾患感受性遺伝子による病態の解明 | 日本消化器病学会雑誌 | 110 | 1602-1610 | 2013 |
| 下田慎治, 中村 稔, 石橋大海 | PBC の発症機序 | 肝臓 | 54 (10) | 676-681 | 2013 |

| | | | | | |
|---|---|---------------------------------------|--------|---|------|
| 石橋大海 | 【稀少疾患】原発性胆汁性肝硬変. ケア ネット CareNet | | | http://www.carenet.com/ | 2014 |
| 石橋大海, 小森敦正 | UDCA 使用中の原発性胆汁性肝硬変 (PBC)患者に対するベザフィブラートの 併用効果 | Minds トピックス | | | 2014 |
| 大平弘正, 原田憲一, 下田慎治, 中村 稔 | PBC 最近の話題 | 日本消化器病学会雑誌 | 110 | 29-43 | 2013 |
| 中村 稔 | ゲノムワイド関連解析による日本人原 発性胆汁性肝硬変の疾患感受性遺伝子、 <i>TNFSF15</i> 、 <i>POU2AF1</i> の同定 | 分子消化器病 | 10 (1) | 85-89 | 2013 |
| 中村 稔 | PBC の治療反応性と予後予測 —厚生 労働省研究班による多施設の PBC 研究 成果— | たんじゅうさん | 12 (2) | 16-117 | 2013 |
| 中村 稔, 西田奈央, 川嶋実苗, 相葉佳洋 小森敦正, 八橋 弘, 徳永勝士, 国立病院機 構肝ネットワーク PBC 研究班、厚生労働省難 治性疾患克服研究事 業・難治性の肝胆臓疾 患に関する調査研究班 | 原発性胆汁性肝硬変(PBC)の疾患感受性 遺伝子による病態の解明 | 第 20 回浜名湖シンポ ジウム記録集 ゲノ ム情報の臨床応用 | | 74-78 | 2013 |
| 相葉佳洋, 小森敦正, 長岡進矢, 阿比留正剛, 右田清志, 伊東正博, 石橋大海, 八橋 弘, 中村 稔 | 原発性胆汁性肝硬変患者における TL1A と DcR3 の臨床学的意義 | 消化器と免疫 | 49 | 15-17 | 2013 |
| 原田憲一, 中村 稔, 下田慎治, 中沼安二 | 原発性胆汁性肝硬変における血中 Fractalkine の意義 | 消化器と免疫 | 49 | 12-14 | 2013 |
| Aiba Y, <u>Nakamura M.</u> | The role of TL1A and DR3 in autoimmune and inflammatory diseases. | Mediators Inflamm | | In press | |
| Aiba Y, Harada K, Komori A, Ito M, <u>Shimoda S</u> , Nakamura H, Nagaoka S, Abiru S, Migita K, <u>Ishibashi H</u> , <u>Nakanuma Y</u> , Nishida N, Kawashima M, Tokunaga K, Yatsuhashi H, <u>Nakamura M.</u> | Systemic and local expression levels of TNF-like ligand 1A and its decoy receptor 3 are increased in primary biliary cirrhosis. | Liver Int | | In press | |

| | | | | | |
|---|--|------------------------------|---------|-----------|------|
| Harada K, Kakuda Y, <u>Nakamura M</u> , <u>Shimoda S</u> , <u>Nakanuma Y</u> . | Clinicopathological significance of serum fractalkine in primary biliary cirrhosis | Dig Dis Sci | 58 | 3037-3043 | 2013 |
| Ohishi Y, <u>Nakamura M</u> , Ishikawa N, Saitoh O, Nakamura H, Aiba Y, Komori A, Migita K, Yatsuhashi H, Fukushima N, Kohjima M, Yoshimoto T, Fukuizumi K, Ishibashi M, Nishino T, Shirabe K, Taketomi A, <u>Maehara Y</u> , <u>Ishibashi H</u> , <u>Nakamura M</u> ; PBC Study Group of NHOSLJ. | Genetic polymorphisms of OCT-1 confer susceptibility to severe progression of primary biliary cirrhosis in Japanese patients. | J Gastroenterol | 49 (2) | 332-342 | 2014 |
| 田中篤, <u>田妻進</u> , 岡崎和一, <u>坪内博仁</u> , 乾和郎, <u>滝川一</u> | 硬化性胆管炎の全国調査 | 胆道 | 27 (2) | 176-187 | 2013 |
| Tanaka A, <u>Takikawa H</u> . | Geoeidemiology of primary sclerosing cholangitis: A critical review. | J Autoimmunity | 46 | 35-40 | 2013 |
| Tanaka A, <u>Tazuma S</u> , Okazaki K, <u>Tsubouchi H</u> , Inui K, <u>Takikawa H</u> . | Nationwide survey for primary sclerosing cholangitis and IgG4-related sclerosing cholangitis in Japan. | J Hepatobiliary Pancreat Sci | 21 | 43-50 | 2014 |
| Harada K, Hsu M, Ikeda H, <u>Zeniya M</u> , <u>Nakanuma Y</u> . | Application and Validation of a New Histologic Staging and Grading System for Primary Biliary Cirrhosis. | J Clin Gastroenterol | 47 (2) | 174-181 | 2013 |
| Kakuda Y, Harada K, Sawada-Kitamura S, Ikeda H, Sato Y, Sasaki M, Okafuji H, Mizukoshi E, Terasaki S, Ohta H, Kasashima S, Kawashima A, Kaizaki Y, Kaneko S, <u>Nakanuma Y</u> . | Evaluation of a new histologic staging and grading system for primary biliary cirrhosis in comparison with classical systems. | Hum Pathol | 44 (6) | 1107-1117 | 2013 |
| Okamura A, Harada K, Nio M, <u>Nakanuma Y</u> . | Participation of natural killer cells in the pathogenesis of bile duct lesions in biliary atresia. | J Clin Pathol | 66 (2) | 99-108 | 2013 |
| Nozaki Y, Harada K, Sanzen T, <u>Nakanuma Y</u> . | PPAR γ ligand attenuates portal inflammation in the MRL-lpr mouse: a new strategy to restrain cholangiopathy in primary biliary cirrhosis. | Med Mol Morphol | 46 (3) | 153-159 | 2013 |
| Okamura A, Harada K, Nio M, <u>Nakanuma Y</u> . | Interleukin-32 production associated with biliary innate immunity and proinflammatory cytokines contributes to the pathogenesis of cholangitis in biliary atresia. | Clin Exp Immunol | 173 (2) | 268-275 | 2013 |

| | | | | | |
|---|---|-----------------|---------|-----------|------|
| Harada K, <u>Hirohara J</u> , <u>Ueno Y</u> , Nakano T, Kakuda Y, <u>Tsubouchi H</u> , Ichida T, <u>Nakanuma Y</u> . | Incidence of and risk factors for hepatocellular carcinoma in primary biliary cirrhosis: National data from Japan. | Hepatology | 57 (5) | 1942-1949 | 2013 |
| Harada K, Kakuda Y, <u>Nakamura M</u> , <u>Shimoda S</u> , <u>Nakanuma Y</u> . | Clinicopathological significance of serum fractalkine in primary biliary cirrhosis. | Dig Dis Sci | 58 (10) | 3037-3043 | 2013 |
| Harada K, <u>Nakanuma Y</u> . | Prevalence and risk factors of hepatocellular carcinoma in Japanese patients with primary biliary cirrhosis. | Hepato Res | 44 (2) | 133-140 | 2014 |
| Harada K, Kakuda Y, Sato Y, Ikeda H, <u>Shimoda S</u> , Yamamoto Y, Inoue H, Ohta H, Kasashima S, Kawashima A, <u>Nakanuma Y</u> . | Alteration of energy metabolism in the pathogenesis of bile duct lesions in primary biliary cirrhosis. | J Clin Pathol | | In press | |
| 原田憲一, <u>中沼安二</u> | 原発性胆汁性肝硬変の新しい病期分類・活動度分類 | 病理と臨床 | 31 (2) | 210-212 | 2013 |
| 角田優子, 齊川邦和, 松下信之, 原田憲一, <u>中沼安二</u> | <短報>オルセイン染色の実態調査結果と標準化への試み | 肝臓 | 54 (10) | 716-719 | 2013 |
| Ogawa E, Furusyo N, Kajiwara E, Takahashi K, Nomura H, Maruyama T, Tanabe Y, Satoh T, <u>Nakamuta M</u> , Kotoh K, Azuma K, Dohmen K, <u>Shimoda S</u> , Hayashi J; Kyushu University Liver Disease Study (KULDS) Group. | Efficacy of pegylated interferon alpha-2b and ribavirin treatment on the risk of hepatocellular carcinoma in patients with chronic hepatitis C: A prospective, multicenter study. | J Hepatol | 58 (3) | 495-501 | 2013 |
| Ikegami T, Shirabe K, Fukuhara T, Furusyo N, Kotoh K, Kato M, <u>Shimoda S</u> , Aishima S, Soejima Y, Yoshizumi T, <u>Maehara Y</u> . | Early extensive viremia, but not rs8099917 genotype, is the only predictor for cholestatic hepatitis C after living-donor liver transplantation. | Hepato Res | 43(6) | 621-629 | 2013 |
| Ikegami T, Shirabe K, Yoshizumi T, Furusyo N, Kotoh K, Kato M, <u>Shimoda S</u> , Soejima Y, Motomura T, Fukuhara T, <u>Maehara Y</u> . | Impact of conversion from pegylated interferon- α 2b to interferon- α 2a for treating recurrent hepatitis C after liver transplantation. | Transplantation | 95 (6) | e38-42 | 2013 |
| Furusyo N, Ogawa E, <u>Nakamuta M</u> , Kajiwara E, Nomura H, Dohmen K, Takahashi K, Satoh T, Azuma K, Kawano A, | Telaprevir can be successfully and safely used to treat older patients with genotype 1b chronic hepatitis C. | J Hepatol | 59 (2) | 205-212 | 2013 |

| | | | | | |
|---|---|------------------|---------|-----------|------|
| Tanabe Y, Kotoh K, <u>Shimoda S</u> , Hayashi J. | | | | | |
| Ogawa E, Furusyo N, <u>Nakamuta M</u> , Kajiwara E, Nomura H, Dohmen K, Takahashi K, Satoh T, Azuma K, Kawano A, Tanabe Y, Kotoh K, <u>Shimoda S</u> , Hayashi J. | Clinical milestones for the prediction of severe anemia by chronic hepatitis C patients receiving telaprevir-based triple therapy. | J Hepatol | 59 (4) | 667-674 | 2013 |
| Sumida K, <u>Shimoda S</u> , Iwasaka S, Hisamoto S, Kawanaka H, Akahoshi T, Ikegami T, Shirabe K, Shimono N, <u>Maehara Y</u> , Selmi C, Gershwin ME, Akashi K. | Characteristics of Splenic CD8 ⁺ T Cell Exhaustion in Patients with Hepatitis C. | Clin Exp Immunol | 174 (1) | 172-178 | 2013 |
| Honda A, Ikegami T, <u>Nakamura M</u> , Miyazaki T, Iwamoto J, Hirayama T, Saito Y, <u>Takikawa H</u> , Imawari M, <u>Matsuzaki Y</u> . | Anticholestatic effects of bezafibrate in patients with primary biliary cirrhosis treated with ursodeoxycholic acid. | Hepatology | 57 | 1931-1941 | 2013 |
| Tanaka T, Yamashiki N, Sugawara Y, Tamura S, <u>Nakamura M</u> , Kaneko J, Aoki T, Sakamoto Y, Hasegawa K, <u>Kokudo N</u> . | Chronologic changes of explanted liver volume and the use of ursodeoxycholic acid in patients with end-stage primary biliary cirrhosis. | Hepatol Res | | In press | |
| Tanaka T, Sugawara Y, Tamura S, Kaneko J, Takazawa Y, Aoki T, Hasegawa K, Sakamoto Y, Yamashiki N, <u>Kokudo N</u> . | Living donor liver transplantation for non-alcoholic steatohepatitis: A single center experience. | Hepatol Res | | In press | |
| Kaneko J, Sugawara Y, Tamura S, Aoki T, Sakamoto Y, Hasegawa K, Yamashiki N, <u>Kokudo N</u> . | De novo malignancies after adult-to-adult living-donor liver transplantation with a malignancy surveillance program: comparison with a Japanese population-based study. | Transplantation | 95 | 1142-1147 | 2013 |
| Ijichi H, Shirabe K, Taketomi A, Yoshizumi T, Ikegami T, Mano Y, Aishima S, Abe K, Honda H, <u>Maehara Y</u> . | Clinical usefulness of (18) F-fluorodeoxyglucose positron emission tomography/computed tomography for patients with primary liver cancer with special reference to rare histological types, hepatocellular carcinoma with sarcomatous change and combined hepatocellular and cholangiocarcinoma. | Hepatol Res | 43 (5) | 481-487 | 2013 |
| Yoshiya S, Shirabe K, Matsumoto Y, Ikeda T, Soejima Y, Yoshizumi T, Uchiyama H, Ikegami T, Harimoto N, <u>Maehara Y</u> . | Rendezvous ductoplasty for biliary anastomotic stricture after living-donor liver transplantation. | Transplantation | 95 (10) | 1278-1283 | 2013 |

| | | | | | |
|---|--|------------------------|---------|-----------|------|
| Ikegami T, Shirabe K, Nakagawara H, Yoshizumi T, Toshima T, Soejima Y, Uchiyama H, Yamashita Y, Harimoto N, <u>Maehara Y.</u> | Obstructing spontaneous major shunt vessels is mandatory to keep adequate portal inflow in living-donor liver transplantation. | Transplantation | 95 (10) | 1270-1277 | 2013 |
| Yoshizumi T, Ikegami T, Yoshiya S, Motomura T, Mano Y, Muto J, Ikeda T, Soejima Y, Shirabe K, <u>Maehara Y.</u> | Impact of tumor size, number of tumors and neutrophil-to-lymphocyte ratio in liver transplantation for recurrent hepatocellular carcinoma. | Hepato Res | 43 (7) | 709-716 | 2013 |
| Ikegami T, Shirabe K, Yoshiya S, Soejima Y, Yoshizumi T, Uchiyama H, Toshima T, Motomura T, <u>Maehara Y.</u> | One-step reconstruction of the right inferior hepatic veins using auto-venous grafts in living-donor liver transplantation. | Surg Today | 43 (7) | 769-776 | 2013 |
| Morita K, Shirabe K, Yoshizumi T, Ikegami T, Masuda T, Hashimoto N, Mano Y, Miyata T, Soejima Y, <u>Maehara Y.</u> | Feasible isolated liver transplantation for a cirrhotic patient on chronic hemodialysis. | Case Rep Gastroenterol | 7 (2) | 299-303 | 2013 |
| Toshima T, Shimada M, Ikegami T, Utsunomiya T, Ikemoto T, Morine Y, Yoshizumi T, Soejima Y, Shirabe K, <u>Maehara Y.</u> | Fairly rare spontaneous disappearance of a hepatic artery aneurysm following living donor liver transplantation. | Liver Transpl | 19 (8) | 929-930 | 2013 |
| Ikegami T, Imai D, Wang H, Yoshizumi T, Yamashita YI, Ninomiya M, Iguchi T, Bekki Y, Shirabe K, <u>Maehara Y.</u> | D-MELD as a Predictor of Early Graft Mortality in Adult-to-Adult Living-Donor Liver Transplantation. | Transplantation | 97 (4) | 457-462 | 2014 |
| Matsumoto Y, Ikegami T, Morita K, Yoshizumi T, Kayashima H, Shirabe K, <u>Maehara Y.</u> | Renoportals anastomosis in right lobe living donor liver transplantation: report of a case. | Surg Today | 43 (11) | 1316-1320 | 2013 |
| Yoshizumi T, Ikegami T, Toshima T, Harimoto N, Uchiyama H, Soejima Y, Yamashita Y, Shirabe K, <u>Maehara Y.</u> | Two-step selection criteria for living donor liver transplantation in patients with hepatocellular carcinoma. | Transplant Proc | 45 (9) | 3310-3313 | 2013 |
| Harimoto N, Shirabe K, Nakagawara H, Toshima T, Yamashita Y, Ikegami T, Yoshizumi T, Soejima Y, Ikeda T, <u>Maehara Y.</u> | Prognostic factors affecting survival at recurrence of hepatocellular carcinoma after living-donor liver transplantation: with special reference to neutrophil/lymphocyte ratio. | Transplantation | 96 (11) | 1008-1012 | 2013 |
| Renzi A, DeMorrow S, Onori P, Carpino G, Mancinelli R, Meng F, Venter J, White M, Franchitto A, Francis H, | Modulation of the biliary expression of arylalkylamine N-acetyltransferase alters the autocrine proliferative responses of cholangiocytes in rats. | Hepatology | 57 (3) | 1130-1141 | 2013 |

| | | | | | |
|---|--|-----------------|--------|-----------|------|
| Han Y, <u>Ueno Y</u> , Dusio G, Jensen KJ, Greene JJ, Jr., Glaser S, Gaudio E, Alpini G | | | | | |
| Ninomiya M, Kondo Y, Funayama R, Nagashima T, Kogure T, Kakazu E, Kimura O, <u>Ueno Y</u> , Nakayama K, Shimosegawa T. | Distinct microRNAs expression profile in primary biliary cirrhosis and evaluation of miR505-3p and miR197-3p as novel biomarkers. | PloS One | 8 (6) | e66086 | 2013 |
| Mancinelli R, Franchitto A, Glaser S, Meng F, Onori P, Demorrow S, Francis H, Venter J, Carpino G, Baker K, Han Y, <u>Ueno Y</u> , Gaudio E, Alpini G | GABA induces the differentiation of small into large cholangiocytes by activation of Ca(2+)/CaMK I-dependent adenylyl cyclase 8. | Hepatology | 58 (1) | 251-263 | 2013 |
| Osawa Y, Suetsugu A, Matsushima-Nishiwaki R, Yasuda I, <u>Saibara T</u> , Moriwaki H, Seishima M, Kozawa O. | Liver acid sphingomyelinase inhibits growth of metastatic colon cancer. | J Clin Invest | 123 | 834-843 | 2013 |
| Ue M, Ikebe N, Munekage K, Ochi T, Ono M, <u>Saibara T</u> . | Hepatocyte destruction with enhanced collagen synthesis in the liver of chronic hepatitis C patients on hemodialysis. | J Viral Hepat | 20 | 350-357 | 2013 |
| Osawa Y, Hoshi M, Yasuda I, <u>Saibara T</u> , Moriwaki H, Kozawa O. | Tumor necrosis factor- α promotes cholestasis-induced liver fibrosis in the mouse through tissue inhibitor of metalloproteinase-1 production in hepatic stellate cells. | PLoS One | 8 | e65251 | 2013 |
| Yoneda M, Imajo K, Eguchi Y, Fujii H, Sumida Y, Hyogo H, Ono M, Suzuki Y, Kawaguchi T, Aoki N, Sata M, Kanemasa K, Kohgo Y, <u>Saibara T</u> , Chayama K, Itoh Y, Yoshikawa T, Anzai K, Fujimoto K, Okanoue T, Nakajima A; Japan Study Group of Nonalcoholic Fatty Liver Disease. | Noninvasive scoring systems in patients with nonalcoholic fatty liver disease with normal alanine aminotransferase levels. | J Gastroenterol | 48 | 1051-1060 | 2013 |
| <u>Saibara T</u> , Enomoto N, Kaneko S, Chayama K, Sata M, Imawari M, Onishi S, Okita K. | Clinical efficacy of combination therapy with ME3738 and pegylated interferon alpha-2a in patients with hepatitis C virus genotype 1. | Hepatol Res | | In press | |
| Ono M, Ogasawara M, Hirose A, Mogami S, Ootake N, Aritake K, Higuchi T, Okamoto N, | Bofutsushosan, a Japanese herbal (Kampo) medicine, attenuates progression of nonalcoholic steatohepatitis in mice. | J Gastroenterol | | In press | |

| | | | | | |
|---|---|-----------------|----|----------|------|
| Sakamoto S, Yamamoto M, Urade Y, <u>Saibara T</u> , Oben JA. | | | | | |
| Hasegawa T, Yamao K, Hijioaka S, Bhatia V, Mizuno N, Hara K, Imaoka H, Niwa Y, Tajika M, Kondo S, Tanaka T, Shimizu Y, Kinoshita T, Kohsaki T, Nishimori I, Iwasaki S, <u>Saibara T</u> , Hosoda W, Yatabe Y. | Evaluation of Ki-67 index in EUS-FNA specimens for the assessment of malignancy risk in pancreatic neuroendocrine tumors. | Endoscopy | 46 | 32-38 | 2014 |
| Taketani H, Sumida Y, Tanaka S, Imajo K, Yoneda M, Hyogo H, Ono M, Fujii H, Eguchi Y, Kanemasa K, Chayama K, Itoh Y, Yoshikawa T, <u>Saibara T</u> , Fujimoto K, Nakajima A; Japan Study Group of NAFLD | The association of insomnia with gastroesophageal reflux symptoms in biopsy-proven nonalcoholic fatty liver disease. | J Gastroenterol | | In press | 2013 |
| Hashiba M, Ono M, Hyogo H, Ikeda Y, Masuda K, Yoshioka R, Ishikawa Y, Nagata Y, Munekage K, Ochi T, Hirose A, Nozaki-Fujimura Y, Noguchi S, Okamoto N, Chayama K, Suganuma N, <u>Saibara T</u> . | Glycemic variability is an independent predictive factor for development of hepatic fibrosis in nonalcoholic Fatty liver disease. | PLoS One | 8 | e76161 | 2013 |
| Toda K, Hayashi Y, Yamashita A, Okabe M, Ono M, <u>Saibara T</u> . | Aromatase-null mice expressing enhanced green fluorescent protein in germ cells provide a model system to assess estrogen-dependent ovulatory responses. | Transgenic Res | | In press | |
| Nakahara T, Hyogo H, Yoneda M, Sumida Y, Eguchi Y, Fujii H, Ono M, Kawaguchi T, Imajo K, Aikata H, Tanaka S, Kanemasa K, Fujimoto K, Anzai K, <u>Saibara T</u> , Sata M, Nakajima A, Itoh Y, Chayama K, Okanoue T; Japan Study Group of Nonalcoholic Fatty Liver Disease. | Type 2 diabetes mellitus is associated with the fibrosis severity in patients with nonalcoholic fatty liver disease in a large retrospective cohort of Japanese patients. | J Gastroenterol | | In press | |

| | | | | | |
|---|---|-------------------|---------|-----------|------|
| Tanaka K, Hyogo H, Ono M, Takahashi H, Kitajima Y, Ono N, Eguchi T, Fujimoto K, Chayama K, <u>Saibara T</u> , Anzai K, Eguchi Y, Japan Study Group of Nonalcoholic Fatty Liver Disease. | The upper limit of normal serum alanine aminotransferase levels in Japanese subjects. | Hepatol Res | | In press | |
| 越智経浩, 宗景玄祐, 小野正文, <u>西原利治</u> | 非アルコール性脂肪肝(NASH)の診療 | 臨床と研究 | 90 | 183-187 | 2013 |
| <u>西原利治</u> | 非アルコール性脂肪性肝疾患 (NASH/NAFLD) | 日本臨床内科医会誌 | 28 | 11-17 | 2013 |
| <u>西原利治</u> , 羽柴基, 小野正文 | 糖尿病と脂肪肝 | Diabetes Frontier | 24 | 408-411 | 2013 |
| 徳光敬太, 小野正文, <u>西原利治</u> | NAFLD/NASH の疫学 | | 28 | 403-407 | 2013 |
| 宮本敬子, 小野正文, <u>西原利治</u> | 非アルコール性脂肪性肝疾患の疾患関連遺伝子 | 日本消化器病学会雑誌 | 110 | 1597-1601 | 2013 |
| 十河剛, 森實雅司, 乾あやの, 藤澤知雄 | 小児急性肝不全の内科的治療戦略 | 日本小児科学会誌 | 117 (4) | 718-731 | 2013 |
| 持田 智, 滝川康裕, 中山伸朗, 桶谷 真, 内木隆文, 山岸由幸, 藤原慶一, <u>市田隆文</u> , 坪内博仁 | 急性肝不全の成因分類 | 肝臓 | | In press | |
| 藤原慶一, 織田成人, 井上和明, 荒田慎寿, 安部隆三, 滝川康裕, 井戸章雄, 持田 智, 坪内博仁, 横須賀収 | 急性肝不全に対する人工肝補助療法についての提言: high-flow CHDF, on-line HDF による覚醒率向上の認識とその全国標準化の必要性 | 肝臓 | | In press | |
| <u>Mochida S</u> , Takikawa Y, Nakayama N, Oketani M, Naiki T, Yamagishi Y, Fujiwara K, <u>Ichida K</u> , <u>Tsubouchi H</u> . | Classification of the etiologies of acute liver failure in Japan: A report by the Intractable Hepato-Biliary Diseases Study Group of Japan. | Hepatol Res | | In press | |
| Harigai M, <u>Mochida S</u> , Mimura T, Koike T, Miyasaka N. | A proposal for management of rheumatic disease patients with hepatitis B virus infection receiving immunosuppressive therapy. | Mod Rheumatol | 24 | 1-7 | 2014 |

| | | | | | |
|---|---|--------------------------------|----|-----------|------|
| Nakayama N, Oketani M, Kawamura Y, Inao M, Nagoshi S, Fujiwara K, Tsubouchi H, Mochida S. | Algorithm to determine the outcome of patients with acute liver failure: a data mining analysis using decision trees. | J Gastroenterol | 47 | 664-677 | 2012 |
| Sugawara K, Nakayama N, Mochida S. | Acute liver failure in Japan: definition, classification, and prediction of the outcome. | J Gastroenterol | 47 | 849-861 | 2012 |
| Fujiwara K, Yasui S, Yokosuka O. | Autoimmune acute liver failure: An emerging etiology for intractable acute liver failure. (Review). | Hepatol Int | 7 | 335-346 | 2013 |
| Fujiwara K, Yasui S, Yonemitsu Y, Mikata R, Arai M, Kanda T, Imazeki F, Oda S, Yokosuka O. | Efficacy of high-dose corticosteroid in the early stage of viral acute liver failure. | Hepatol Res | | In press | |
| Fujiwara K, Ohtsuka M, Yokosuka O. | Radiological and histological heterogeneity in a case of autoimmune acute liver failure. | Clin Gastroenterol Hepatol | | In press | |
| Fujiwara K, Yasui S, Yokosuka O. | Treatment of autoimmune acute liver failure beyond consensus guidelines. | Aliment Pharmacol Ther | 38 | 1143-1144 | 2013 |
| Fujiwara K, Seza K, Fukuda Y, Nakano M, Yokosuka O. | A case of primary biliary cirrhosis and autoimmune hepatitis overlap showing acute presentation and transient seropositivity for immunoglobulin G and anti-nuclear antibody. | Clin J Gastroenterol | 6 | 465-469 | 2013 |
| Fujiwara K, Yasui S, Yokosuka O. | Corticosteroid for severe acute exacerbation of chronic hepatitis B. | Eur J Gastroenterol Hepatol | 25 | 1492 | 2013 |
| Kato A, Tanaka H, Kawaguchi T, Kanazawa H, Iwasa M, Sakaïda I, Moriwaki H, Murawaki Y, Suzuki K, Okita K. | Nutritional management contributes to improvement in minimal hepatic encephalopathy and quality of life in patients with liver cirrhosis: A preliminary, prospective, open-label study. | Hepatol Res | 43 | 452-458 | 2013 |
| Takase HM, Itoh T, Ino S, Wang T, Koji T, Akira S, Takikawa Y, Miyajima A. | FGF7 is a functional niche signal required for stimulation of adult liver progenitor cells that support liver regeneration. | Genes Dev | 27 | 169 - 181 | 2013 |
| Takikawa Y, Harada M, Wang T, Suzuki K. | Usefulness and accuracy of the international normalized ratio and activity percent of prothrombin time in patients with liver disease. | Hepatol Res | | In press | |
| Kakisaka K, Takikawa Y. | Elevation of serum cytokines preceding elevation of liver enzymes in a case of drug-induced liver injury. | Hepatol Res | | In press | |

| | | | | | |
|--|---|--------------------|-----|-----------|------|
| Wang T, Takikawa Y, Watanabe A, Kakisaka K, Oikawa K, Miyamoto Y, <u>Suzuki K.</u> | Proliferation of mouse liver stem/progenitor cells induced by plasma from patients with acute liver failure is modulated by P2Y2 receptor-mediated JNK activation. | J Gastroenterol | | In press | |
| 滝川康裕, 鈴木一幸 | 肝疾患 急性肝不全の予後 | 肝胆脾 | 66 | 391-393 | 2013 |
| 滝川康裕 | 急性肝不全の診断基準 | Modern Physician | 33 | 515 - 518 | 2013 |
| Kochi T, Shimizu M, Terakura D, Baba A, Ohno T, Kubota M, Shirakami Y, Tsurumi H, Tanaka T, <u>Moriwaki H.</u> | Non-alcoholic steatohepatitis and preneoplastic lesions develop in the liver of obese and hypertensive rats: Suppressing effects of EGCG on the development of liver lesions. | Cancer Lett | 342 | 60-69 | 2014 |
| Shimizu M, Tanaka T, <u>Moriwaki H.</u> | Obesity and hepatocellular carcinoma: targeting obesity-related inflammation for chemoprevention of liver carcinogenesis. | Semin Immunopathol | 35 | 191-202 | 2013 |
| Shiraki M, Nishiguchi Y, Saito M, Fukuzawa Y, Mizuta T, Kaibori M, Hanai T, Nishimura K, Shimizu M, Tsurumi H, <u>Moriwaki H.</u> | Nutritional status and quality of life in current patients with liver cirrhosis as assessed in 2007-2011. | Hepato Res | 43 | 106-112 | 2013 |
| Nagano J, Shimizu M, Hara T, Shirakami Y, Kochi T, Nakamura N, Ohtaki H, Ito H, Tanaka T, Tsurumi H, Saito K, Seishima M, <u>Moriwaki H.</u> | Effects of indoleamine 2,3-dioxygenase deficiency on high-fat diet-induced hepatic inflammation. | PLoS One | 8 | e73404 | 2013 |
| Baba A, Shimizu M, Ohno T, Shirakami Y, Kubota M, Kochi T, Terakura D, Tsurumi H, <u>Moriwaki H.</u> | Synergistic growth inhibition by acyclic retinoid and phosphatidylinositol 3-kinase inhibitor in human hepatoma cells. | BMC Cancer | 13 | 465 | 2013 |
| Takaguchi K, <u>Moriwaki H.</u> , Doyama H, Iida M, Yagura M, Shimada N, Kang M, Yamada H, Kumada H. | Effects of branched-chain amino acid granules on serum albumin level and prognosis are dependent on treatment adherence in patients with liver cirrhosis. | Hepato Res | 43 | 459-466 | 2013 |
| Izumi N, Asahina Y, Kurosaki M, Yamada G, Kawai T, Kajiwara E, Okamura Y, Takeuchi T, Yokosuka O, Kariyama K, Toyoda J, | Inhibition of hepatocellular carcinoma by PegIFN α -2a in patients with chronic hepatitis C: a nationwide multicenter cooperative study. | J Gastroenterol | 48 | 382-390 | 2013 |